PURPOSE: It has been indicated that activated hepatic stellate cells (HSCs) play key roles on the pathogenesis of hepatocellular carcinoma (HCC). The purpose of the study was to investigate the potential mechanism in it. METHODS: Activation of HSCs, the expression of myocyte enhancer factor 2 (MEF2), class II histone deacetylases (II HDACs) and histone acetylation were analyzed in specimens of primary HCCs, cirrhotic and normal livers. Activated HSCs were identified using anti-a-smooth muscle actin (a-SMA) by Immunohistochemistry (IHC). The levels of expression of MEF2A, MEF2C and II HDACs mRNA and protein were measured by real time quantitative PCR and western blot (WB). Histone acetylation was assessed using anti-acetyl-histone H3, -H4 by WB and IHC. A P value < 0.05 was considered statistically significant. RESULTS: A-SMA positive activated HSCs were more prominent in HCCs and cirrhotic livers than in normal livers, accompanied by marked expression of MEF2A and MEF2C. The expression of MEF2A, MEF2C and II HDACs, both mRNA and protein, were much more enhanced in HCCs than those in cirrhotic and normal livers (P < 0.05). Histone H3 and H4 were hyperacetylated in HCCs compared with those in cirrhotic and normal livers (P < 0.05). The correlation coefficients between the expression of MEF2 and II HDACs, acetyl-histones were all beyond 0.5. CONCLUSIONS: These data showed a potential molecular mechanism that activated HSCs participate in the pathogenesis of HCCs by overexpression of MEF2 and its consequent impact on histone hyperacetylation. Further investigations aimed at interfering MEF2 expression are needed.
PURPOSE: It has been indicated that activated hepatic stellate cells (HSCs) play key roles on the pathogenesis of hepatocellular carcinoma (HCC). The purpose of the study was to investigate the potential mechanism in it. METHODS: Activation of HSCs, the expression of myocyte enhancer factor 2 (MEF2), class II histone deacetylases (II HDACs) and histone acetylation were analyzed in specimens of primary HCCs, cirrhotic and normal livers. Activated HSCs were identified using anti-a-smooth muscle actin (a-SMA) by Immunohistochemistry (IHC). The levels of expression of MEF2A, MEF2C and II HDACs mRNA and protein were measured by real time quantitative PCR and western blot (WB). Histone acetylation was assessed using anti-acetyl-histone H3, -H4 by WB and IHC. A P value < 0.05 was considered statistically significant. RESULTS:A-SMA positive activated HSCs were more prominent in HCCs and cirrhotic livers than in normal livers, accompanied by marked expression of MEF2A and MEF2C. The expression of MEF2A, MEF2C and II HDACs, both mRNA and protein, were much more enhanced in HCCs than those in cirrhotic and normal livers (P < 0.05). Histone H3 and H4 were hyperacetylated in HCCs compared with those in cirrhotic and normal livers (P < 0.05). The correlation coefficients between the expression of MEF2 and II HDACs, acetyl-histones were all beyond 0.5. CONCLUSIONS: These data showed a potential molecular mechanism that activated HSCs participate in the pathogenesis of HCCs by overexpression of MEF2 and its consequent impact on histone hyperacetylation. Further investigations aimed at interfering MEF2 expression are needed.
Authors: Jean S Campbell; Steven D Hughes; Debra G Gilbertson; Thomas E Palmer; Matthew S Holdren; Aaron C Haran; Melissa M Odell; Renay L Bauer; Hong-Ping Ren; Harald S Haugen; Matthew M Yeh; Nelson Fausto Journal: Proc Natl Acad Sci U S A Date: 2005-02-22 Impact factor: 11.205
Authors: Francisco J Naya; Brian L Black; Hai Wu; Rhonda Bassel-Duby; James A Richardson; Joseph A Hill; Eric N Olson Journal: Nat Med Date: 2002-10-15 Impact factor: 53.440
Authors: J Gotzmann; A N M Fischer; M Zojer; M Mikula; V Proell; H Huber; M Jechlinger; T Waerner; A Weith; H Beug; W Mikulits Journal: Oncogene Date: 2006-05-25 Impact factor: 9.867
Authors: David B Seligson; Steve Horvath; Tao Shi; Hong Yu; Sheila Tze; Michael Grunstein; Siavash K Kurdistani Journal: Nature Date: 2005-06-30 Impact factor: 49.962
Authors: Kodihalli C Ravindra; Vivek Narayan; Gerald H Lushington; Blake R Peterson; K Sandeep Prabhu Journal: Chem Res Toxicol Date: 2011-12-16 Impact factor: 3.739
Authors: Kodihalli C Ravindra; B Ruthrotha Selvi; Mohammed Arif; B A Ashok Reddy; Gali R Thanuja; Shipra Agrawal; Suman Kalyan Pradhan; Natesh Nagashayana; Dipak Dasgupta; Tapas K Kundu Journal: J Biol Chem Date: 2009-07-01 Impact factor: 5.157
Authors: Shunsuke Ichi; Fabricio F Costa; Jared M Bischof; Hiromichi Nakazaki; Yueh-Wei Shen; Vanda Boshnjaku; Saurabh Sharma; Barbara Mania-Farnell; David G McLone; Tadanori Tomita; Marcelo B Soares; Chandra S K Mayanil Journal: J Biol Chem Date: 2010-09-10 Impact factor: 5.157
Authors: Junko Suzuki; Yunn-Yi Chen; Gary K Scott; Sandy Devries; Koei Chin; Christopher C Benz; Frederic M Waldman; E Shelley Hwang Journal: Clin Cancer Res Date: 2009-04-21 Impact factor: 12.531
Authors: Yuri Kim; Dillon Phan; Eva van Rooij; Da-Zhi Wang; John McAnally; Xiaoxia Qi; James A Richardson; Joseph A Hill; Rhonda Bassel-Duby; Eric N Olson Journal: J Clin Invest Date: 2008-01 Impact factor: 14.808